Author

Anwar Almajdi

Observed names: A Almajdi, A., Almajdi

Institutions: Jahra Hospital, Ministry of Health

Observed institutions: Mubarak Al Kabeer Hospital, Jahra Hospital, Kuwait University, Ministry of Health

ORCID: 0009-0004-9313-5437

Observed ORCID: 0009-0004-9313-5437

OpenAlex ID: A5092393774

Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis

2023 · Anwar Almajdi, Sara Almutairi, et al. · Thrombosis Research · 14

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study

2025 · Mohammad Shehab, Anwar Almajdi, et al. · Journal of Clinical Medicine · 3

From Conventional Therapy to Precision Medicine in Inflammatory Bowel Disease: A State-of-the-Art Review

2026 · Anwar Almajdi, Mohammad Shehab · Biomedicines · 2

Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis

2026 · Anwar Almajdi, Sara Almutairi, et al. · Research and Practice in Thrombosis and Haemostasis · 2

Vancomycin for the Induction and Maintenance of Remission in Biologics Refractory Patient with Ulcerative Colitis and Primary Sclerosing Cholangitis Post-Liver and Bone Marrow Transplantation

2025 · Mohammad Shehab, Anwar Almajdi, et al. · Case Reports in Gastroenterology · 2

Correction: Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study

2026 · Mohammad Shehab, Anwar Almajdi, et al. · Frontiers in Pharmacology

Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study

2026 · Mohammad Shehab, Anwar Almajdi, et al. · Frontiers in Pharmacology

P0676 Safety and Effectiveness of Multi-Switch between Adalimumab Originator and Biosimilars in Inflammatory Bowel Disease: A Multicenter (SUSTAIN) Study

2026 · M Shehab, A Almajdi, et al. · Journal of Crohn s and Colitis

P0916 Predictors of Ustekinumab Intensified Dose Escalation in Inflammatory Bowel Disease: A Real-World (UST-PREDICT) Study

2026 · M Shehab, F Alrashed, et al. · Journal of Crohn s and Colitis

Works count: 10

Citation count: 23

H-index: 2

I10-index: 1